Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL – Get Free Report) and Helius Medical Technologies (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares Pheton Holdings Ltd Class A Ordinary Shares and Helius Medical Technologies’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Pheton Holdings Ltd Class A Ordinary Shares | N/A | N/A | N/A |
Helius Medical Technologies | -1,764.74% | -244.82% | -127.10% |
Institutional & Insider Ownership
18.6% of Helius Medical Technologies shares are held by institutional investors. 5.1% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pheton Holdings Ltd Class A Ordinary Shares | $572,291.00 | 23.63 | N/A | N/A | N/A |
Helius Medical Technologies | $502,000.00 | 3.52 | -$8.85 million | ($6.18) | -0.08 |
Pheton Holdings Ltd Class A Ordinary Shares has higher revenue and earnings than Helius Medical Technologies.
Analyst Recommendations
This is a breakdown of recent ratings for Pheton Holdings Ltd Class A Ordinary Shares and Helius Medical Technologies, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pheton Holdings Ltd Class A Ordinary Shares | 0 | 0 | 0 | 0 | 0.00 |
Helius Medical Technologies | 0 | 1 | 1 | 0 | 2.50 |
Helius Medical Technologies has a consensus target price of $24.00, indicating a potential upside of 4,968.64%. Given Helius Medical Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Helius Medical Technologies is more favorable than Pheton Holdings Ltd Class A Ordinary Shares.
About Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded on November 2, 2022 and is headquartered in Beijing, China.
About Helius Medical Technologies
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for Pheton Holdings Ltd Class A Ordinary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pheton Holdings Ltd Class A Ordinary Shares and related companies with MarketBeat.com's FREE daily email newsletter.